演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

SOD2高発現は腎癌予後不良因子である

演題番号 : P34-1

[筆頭演者]
演者)吉田 哲也:1 
[共同演者]
影山 進:1、礒野 高敬:2、湯浅 健:3、九嶋 亮治:4、河内 明宏:1、茶野 徳宏:4

1:滋賀医科大学・泌尿器科、2:滋賀医科大学・実験実習支援センター、3:がん研究会有明病院・泌尿器科、4:滋賀医科大学・臨床検査医学

 

Objectives: To investigate the significance of superoxide dismutase 2 (SOD2) as a clinical biomarker in patients with renal cell carcinomas (RCC).
Methods: Ninety-seven patients who underwent radical or partial nephrectomy for the treatment of RCCs were analyzed retrospectively using various clinical parameters and SOD2 expression in the tumors by immunohistochemistry.
Results: The median age of the patients was 62 years. T stages included 68 pT1, 4 pT2, 19 pT3, and 6 pT4. Histological grading 3 was 18. The median follow-up period was 30 months. Twenty-seven patients underwent cytoreductive nephrectomy. A total of 25 patients were treated with molecular targeting therapies. A total of 26 were categorized as high SOD2. High SOD2 expression in the tumors was significantly associated with a worse overall survival (log-rank test, p = 0.005). In particular, in cases with metastatic RCCs, high SOD2 expression was significantly associated with a worse overall survival (log-rank test, p = 0.001) and the maximum critical risk (multivariate Cox proportional hazard ratio=5.20, p = 0.034). In cases with molecular targeting therapies, high SOD2 expression was significantly associated with a worse overall survival (log-rank test, p = 0.003).
Conclusions: High SOD2 expression can be predictive of a poor clinical outcome and be clinically useful in the follow-up of metastatic RCCs. Therapeutics for metastatic RCCs require further improvement, such as supplementary administration of agents targeting mitochondrial SOD2.

キーワード

臓器別:腎・尿路・膀胱

手法別:バイオマーカー

前へ戻る